Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of PEG-rhG-CSF (Jinyouli) in Children with ALL
NCT02953730Phase 4Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Sep 2015
- Primary completion
- Jun 2016
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in neutropenia, sponsored by Chinese Academy of Medical Sciences. Primary endpoints: Peak Concentration at 1 year, Elimination Half Life at 1 year and 1 more. Started Sep 2015; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02953730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953730.